litlas
Log inCreate account

Hossein Borghaei

Active 2009–2025

114
Papers
29,005
Citations
64
h-index
105
i10-index

Citations

Citations per year for Hossein Borghaei1976: 1 citations1990: 1 citations2000: 1 citations2001: 2 citations2003: 1 citations2004: 1 citations2005: 1 citations2006: 1 citations2007: 2 citations2008: 1 citations2009: 3 citations2010: 7 citations2011: 19 citations2012: 18 citations2013: 35 citations2014: 75 citations2015: 109 citations2016: 145 citations2017: 251 citations2018: 490 citations2019: 1,586 citations2020: 2,020 citations2021: 1,939 citations2022: 1,525 citations2023: 1,124 citations2024: 1,683 citations2025: 896 citations2026: 15 citations1977–1989: no citations, so these years are not shown1991–1999: no citations, so these years are not shown2002: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,463 citing papers, 23.8% of this breakdownChina: 2,636 citing papers, 18.1% of this breakdownItaly: 785 citing papers, 5.4% of this breakdownJapan: 660 citing papers, 4.5% of this breakdownFrance: 655 citing papers, 4.5% of this breakdownUnited Kingdom: 627 citing papers, 4.3% of this breakdownGermany: 600 citing papers, 4.1% of this breakdownSpain: 538 citing papers, 3.7% of this breakdownCanada: 424 citing papers, 2.9% of this breakdownSouth Korea: 381 citing papers, 2.6% of this breakdownAustralia: 352 citing papers, 2.4% of this breakdownSwitzerland: 327 citing papers, 2.3% of this breakdown
0%23.8%Other 21.4%

Institutions

Fields

  • Medicine79.1%
  • Biochemistry, Genetics and Molecular Biology13.9%
  • Immunology and Microbiology4.1%
  • Engineering0.8%
  • Neuroscience0.4%
  • Computer Science0.3%
  • Other1.4%

Topics

  • Cancer Immunotherapy and Biomarkers18.4%
  • Lung Cancer Treatments and Mutations9%
  • Lung Cancer Research Studies6%
  • Immunotherapy and Immune Responses4.6%
  • Lung Cancer Diagnosis and Treatment4%
  • CAR-T cell therapy research3.6%
  • Other54.4%

Coauthors

All papers

Open in search
  1. Sotorasib for Lung Cancers with KRAS p.G12C Mutation

    Authors: Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, Timothy Price, Gerald S. Falchook, Jürgen Wolf, Antoîne Italiano, Martin Schüler, Hossein Borghaei, Fabrice Barlési, Terufumi Kato, Alessandra Curioni‐Fontecedro, Adrian G. Sacher, Alexander I. Spira, Suresh S. Ramalingam, Toshiaki Takahashi, Benjamin Besse, Abraham Anderson, Agnes Ang, Qui Tran, Omar Mather, Haby Henary, Gataree Ngarmchamnanrith, Gregory Friberg, Vamsidhar Velcheti, Ramaswamy Govindan - New England Journal of Medicine 2021 cited by 1,769

  2. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

    Authors: Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro, Bogdan Żurawski, Sang‐We Kim, Enric Carcereny, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez, Hiroshi Sakai, István Albert, A. Vergnenègre, Solange Peters, Konstantinos Syrigos, Fabrice Barlési, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, William J. Geese, Prabhu Bhagavatheeswaran, Sridhar K. Rabindran, Ravi S. Kasinathan, Faith E. Nathan, Suresh S. Ramalingam - New England Journal of Medicine 2019 cited by 2,835

  3. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

    Authors: Myung‐Ju Ahn, Byoung Chul Cho, Enriqueta Felip, Ippokratis Korantzis, Kadoaki Ohashi, Margarita Majem, Óscar Juan, Sabin Handzhiev, Hiroki Izumi, Jong Seok Lee, Rafał Dziadziuszko, Jürgen Wolf, Fiona Blackhall, Martin Reck, Jean Bustamante Alvarez, Horst-Dieter Hummel, Anne‐Marie C. Dingemans, Jacob Sands, Hiroaki Akamatsu, Taofeek K. Owonikoko, Suresh S. Ramalingam, Hossein Borghaei, Melissa L. Johnson, Shuang Huang, Sujoy Mukherjee, Mukul Minocha, Tony Jiang, Pablo Martínez, Erik S. Anderson, Luis Paz‐Ares - New England Journal of Medicine 2023 cited by 482

  4. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    Authors: Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak A. Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie R. Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Chang Han, Joseph D. Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith E. Nathan, Luis Paz‐Ares - New England Journal of Medicine 2018 cited by 3,137

  5. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    Authors: David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski - New England Journal of Medicine 2017 cited by 2,575

  6. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

    Authors: Julie R. Brahmer, Jong-Seok Lee, Tudor–Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, László Urbán, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Adam Płużański, Jacobus A. Burgers, Mauricio Mahave, Samreen Ahmed, Adam J. Schoenfeld, Luis Paz‐Ares, Martin Reck, Hossein Borghaei, Kenneth J. O’Byrne, Ravi G. Gupta, Judith Bushong, Li Li, Steven I. Blum, Laura J. Eccles, Suresh S. Ramalingam - Journal of Clinical Oncology 2022 cited by 381

  7. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

    Authors: Luis Paz‐Ares, Stéphane Champiat, W. Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa L. Johnson, Neeltje Steeghs, Fiona Blackhall, Afshin Dowlati, Noemı́ Reguart, Tatsuya Yoshida, Kai He, Shirish M. Gadgeel, Enriqueta Felip, Yiran Zhang, Amrita Pati, Mukul Minocha, Sujoy Mukherjee, Amanda Goldrick, Dirk Nagorsen, Nooshin Hashemi Sadraei, Taofeek K. Owonikoko - Journal of Clinical Oncology 2023 cited by 294

  8. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

    Authors: Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Laura Q.M. Chow, Marco Angelo Burgio, Javier de Castro, Adam Płużański, Óscar Arrieta, Osvaldo Arén Frontera, Rita Chiari, Charles Butts, Joanna Wójcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip, M. Alonso Garcìa, David Waterhouse, Manuel Dómine, Fabrice Barlési, Scott Antonia, M Wohlleber, David E. Gerber, Grzegorz Czyżewicz, David R. Spigel, Lucio Crinò, Wilfried Eberhardt, Ang Li, S. Marimuthu, Julie R. Brahmer - Journal of Clinical Oncology 2021 cited by 661

  9. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

    Authors: Matthew D. Hellmann, Tavi Nathanson, Hira Rizvi, Ben Creelan, Francisco Sánchez-Vega, Arun Ahuja, Ai Ni, Jacki B. Novik, Levi Mangarin, Mohsen Abu-Akeel, Cailian Liu, Jennifer L. Sauter, Natasha Rekhtman, Eliza Chang, Margaret K. Callahan, Jamie E. Chaft, Martin H. Voss, Megan Tenet, Xuemei Li, Kelly L. Covello, Andrea Renninger, Patrik Vitazka, William J. Geese, Hossein Borghaei, Charles M. Rudin, Scott Antonia, Charles Swanton, Jeff Hammerbacher, Taha Merghoub, Nicholas McGranahan, Alexandra Snyder, Jedd D. Wolchok - Cancer Cell 2018 cited by 1,175

  10. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Authors: Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Clarisse Audigier-Valette, Jacobus A. Burgers, Adam Płużański, Randeep Sangha, Carlos Gallardo, Masayuki Takeda, Helena Linardou, Lorena Lupinacci, Ki Hyeong Lee, Claudia Caserta, Mariano Provencio, Enric Carcereny, Gregory A. Otterson, Michael Schenker, Bogdan Żurawski, Aurelia Alexandru, A. Vergnenègre, Judith Raimbourg, Kynan Feeney, Sang‐We Kim, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck - Journal of Thoracic Oncology 2021 cited by 322

  11. First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

    Authors: Neal Ready, Matthew D. Hellmann, Mark M. Awad, Gregory A. Otterson, Martin Gutierrez, Justin F. Gainor, Hossein Borghaei, Jacques Jolivet, Leora Horn, Mihaela Mates, Julie R. Brahmer, Ian Rabinowitz, Pavan S. Reddy, Jason Chesney, James Michael Orcutt, David R. Spigel, Martin Reck, Kenneth J. O’Byrne, Luis Paz‐Ares, Wenhua Hu, Kim E. Zerba, Xuemei Li, Brian Lestini, William J. Geese, Joseph D. Szustakowski, George Green, Chang Han, Suresh S. Ramalingam - Journal of Clinical Oncology 2019 cited by 596

  12. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

    Authors: Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz‐Ares, Adam Płużański, Karen L. Reckamp, Marco Angelo Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlési, Scott Antonia, Óscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer A. Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood‐Chirchir, Diane Healey, Julie R. Brahmer, Wilfried Eberhardt - Journal of Clinical Oncology 2017 cited by 875

  13. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Authors: Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Shadia I. Jalal, Amit Panwalkar, James Chih‐Hsin Yang, Matthew A. Gubens, Lecia V. Sequist, Mark M. Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi - The Lancet Oncology 2016 cited by 1,392

  14. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

    Authors: Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman, Scott Gettinger, Hossein Borghaei, Julie R. Brahmer, Neal Ready, David E. Gerber, Laura Q.M. Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, William J. Geese, Shruti Agrawal, Tina C. Young, Xuemei Li, Scott Antonia - The Lancet Oncology 2016 cited by 961

  15. Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer

    Authors: Julia Judd, Nagla Abdel Karim, Hina Khan, Abdul Rafeh Naqash, Yasmine Baca, Joanne Xiu, Ari M. VanderWalde, Hirva Mamdani, Luis E. Raez, Misako Nagasaka, Sachin Gopalkrishna Pai, Mark A. Socinski, Jorge J. Nieva, Chul Kim, Antoinette J. Wozniak, Chukwuemeka Ikpeazu, Gilberto de Lima Lopes, Alexander I. Spira, W. Michael Korn, Edward S. Kim, Stephen V. Liu, Hossein Borghaei - Molecular Cancer Therapeutics 2021 cited by 186

  16. The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

    Authors: Hermann Einsele, Hossein Borghaei, Robert Z. Orlowski, Marion Subklewe, Gail J. Roboz, Gerhard Zugmaier, Peter Kufer, Karim Iskander, Hagop M. Kantarjian - Cancer 2020 cited by 231

  17. Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)

    Authors: J. Nicholas Bodor, Yanis Boumber, Hossein Borghaei - Cancer 2019 cited by 349

  18. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Authors: Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin, Craig H. Reynolds, Willemijn S.M.E. Theelen, Ivor Percent, V. Gutiérrez Calderón, Melissa L. Johnson, Anne Madroszyk, Edward B. Garon, Kai He, David Planchard, Martin Reck, Sanjay Popat, Roy S. Herbst, Ticiana Leal, Ronald Shazer, Xin Yan, Richard Harrigan, Solange Peters, Isam Abdel-Karim, Mahmoud Abdelsalam, Alfredo Addeo, Carlos Aguado, Patrick Alexander, Jürgen Alt, Georges Azzi, Rama Balaraman, Bonne Biesma, Fiona Blackhall, Sabine Bohnet, Ekaterini Boleti, Hossein Borghaei, Penelope A. Bradbury, Matteo Brighenti, Nicholas Campbell, Toby Campbell, Jean-Luc Canon, Federico Cappuzzo, Enric Carcereny Costa, Luigi Cavanna, Jeremy Cetnar, Antonio Chella, C. Chouaïd, Daniel C. Christoph, J. Cortés Castán, Shaker R. Dakhil, F.J. de Castro Carpeño, Filippo de Marinis, Angelo Delmonte, Ingel Demedts, Wim Demey, Joyce Dits, Maria del Pilar Diz Taín, M. Dómine Gómez, Timothy Dorius, Daphne W. Dumoulin, M. Duruisseaux, Keith D. Eaton, Emilio Esteban González, Devon Evans, Martin Faehling, Nicholas Farrell, Trevor Feinstein, E. Felip Font, M.R. García Campelo, Edward B. Garon, María Pilar Garrido López, Paul Germonpré, Todd Gersten, María González Cao, Srivalli Gopaluni, Laurent Greillier, Francesco Grossi, Florian Guisier, Sarada Gurubhagavatula, Vanesa Gutiérrez Calderón, David Hakimian, Richard D. Hall, Desirée Hao, Ronald Harris, Sayed M.S. Hashemi, Kai He, Lizza Hendriks, Chao Huang, Emad Ibrahim, Sharad Jain, Melissa L. Johnson, B. J. P. Jones, Monte Jones, Óscar Juan, Rosalyn A. Juergens, Courèche Kaderbhaï, Elisabeth A. Kastelijn, Roger Keresztes, Ebenezer A. Kio, Konrad Kokowski, Kartik Konduri, Swati Kulkarni, Jonas Kuon and 84 more - Annals of Oncology 2023 cited by 93

  19. Detection of NRG1 Gene Fusions in Solid Tumors

    Authors: Sushma Jonna, Rebecca Feldman, Jeffrey Swensen, Zoran Gatalica, W. Michael Korn, Hossein Borghaei, C. Patrick, Jorgé Nieva, Alexander I. Spira, Ari M. Vanderwalde, Antoinette J. Wozniak, Edward S. Kim, Stephen V. Liu - Clinical Cancer Research 2019 cited by 229

  20. The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials

    Authors: written on behalf of AME Lung Cancer Collaborative Group, Yangyang Xu, Bing Wan, Xi Chen, Ping Zhan, Yuan Zhao, Tianli Zhang, Hongbing Liu, Muhammad Zubair Afzal, Said Dermime, Steven N. Hochwald, Paul Hofman, Hossein Borghaei, Dang Lin, Tangfeng Lv, Yong‐Seok Song - Translational Lung Cancer Research 2019 cited by 169

  21. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

    Authors: Scott Antonia, Hossein Borghaei, Suresh S. Ramalingam, Leora Horn, Javier de Castro, Adam Płużański, Marco Angelo Burgio, Marina Chiara Garassino, Laura Q.M. Chow, Scott Gettinger, Lucio Crinò, David Planchard, Charles Butts, Alexander Drilon, Joanna Wójcik-Tomaszewska, Gregory A. Otterson, Shruti Agrawal, Ang Li, John R. Penrod, Julie R. Brahmer - The Lancet Oncology 2019 cited by 365

  22. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

    Authors: Scott Gettinger, Naiyer A. Rizvi, Laura Q.M. Chow, Hossein Borghaei, Julie R. Brahmer, Neal Ready, David E. Gerber, Frances A. Shepherd, Scott Antonia, Jonathan W. Goldman, Rosalyn A. Juergens, Scott A. Laurie, Faith E. Nathan, Yun Shen, Christopher Harbison, Matthew D. Hellmann - Journal of Clinical Oncology 2016 cited by 498

  23. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

    Authors: Patrick M. Forde, Valsamo Anagnostou, Zhuoxin Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs, Thomas J. Purcell, Rafael Santana-Dávila, Arkadiusz Z. Dudek, Hossein Borghaei, Mara Lanis, Zineb Belcaid, Kellie N. Smith, Archana Balan, James R. White, Christopher Cherry, I.K. Ashok Sivakumar, Xiaoshan M. Shao, Hok Yee Chan, Dipika Singh, Sampriti Thapa, Peter B. Illei, Drew M. Pardoll, Rachel Karchin, Victor E. Velculescu, Julie R. Brahmer, Suresh S. Ramalingam - Nature Medicine 2021 cited by 128

  24. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016

    Authors: David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, M.C. Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogério Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M.W. Pisters, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, James Stevenson, Steven Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2016 cited by 738